Table 1.
Association between clinicopathological findings and MFAP5 in included triple-negative breast cancer patients
| Characteristics | All (n = 120) | MFAP5 | p-value | MFAP5 (%) | p-value | |||
|---|---|---|---|---|---|---|---|---|
| Low (n = 46) |
High (n = 74) |
Mean ±SD | Median (range) | |||||
| n (%) | n (%) | n (%) | ||||||
| Age (years) | ||||||||
| Mean ±SD | 56.23 ±10.99 | 49.91 ±8.72 | 60.16 ±10.50 | < 0.001a | ||||
| Median (range) | 56 (39–87) | 45 (39–67) | 60 (40–87) | |||||
| ≤ 50 years | 46 (38.3) | 30 (65.2) | 16 (21.6) | 0.001b | 20.21 ±20.62 | 12 (0–56) | < 0.001a | |
| > 50 years | 74 (61.7) | 16 (34.8) | 58 (78.4) | 62.97 ±28.18 | 75 (0–97) | |||
| Size (cm) | ||||||||
| Mean ±SD | 6.33 ±3.59 | 4.04 ±2.71 | 7.75 ±3.34 | < 0.001a | ||||
| Median (range) | 7 (1–13) | 4 (1–9) | 8 (1.5–13) | |||||
| < 5 cm | 48 (40) | 30 (65.2) | 18 (24.3) | 0.004b | 20.79 ±20.37 | 12 (0–56) | < 0.001a | |
| ≥ 5 cm | 72 (60) | 16 (34.8) | 56 (75.7) | 63.77 ±28.15 | 76.50 (0–97) | |||
| Grade | ||||||||
| Grade I | 20 (16.7) | 14 (30.4) | 6 (8.1) | 0.005b | 15.20 ±20.61 | 0 (0–45) | < 0.001a | |
| Grade II | 30 (25) | 18 (39.1) | 12 (16.2) | 24.46 ±19.28 | 20 (0–56) | |||
| Grade III | 70 (58.3) | 14 (30.4) | 56 (75.7) | 65.02 ±27.53 | 78 (0–97) | |||
| Lymph node | ||||||||
| Negative | 38 (31.7) | 38 (82.6) | 0 (0) | < 0.001b | 9.52 ±9.23 | 10 (0–22) | < 0.001a | |
| Positive | 82 (68.3) | 8 (17.4) | 74 (100) | 63.75 ±24.58 | 60 (0–97) | |||
| T | ||||||||
| T1 | 26 (21.7) | 18 (39.1) | 8 (10.8) | 0.003b | 16.84 ±18.20 | 11 (0–50) | < 0.001a | |
| T2 | 22 (18.3) | 12 (26.1) | 10 (13.5) | 25.45 ±22.64 | 22 (0–56) | |||
| T3 | 44 (36.7) | 16 (34.8) | 28 (37.8) | 49.54 ±27.38 | 52 (0–95) | |||
| T4 | 28 (23.3) | 0 (0) | 28 (37.8) | 86.14 ±6.45 | 87 (75–97) | |||
| N | ||||||||
| N0 | 38 (31.7) | 38 (82.6) | 0 (0) | 0.003b | 9.52 ±9.23 | 10 (0–22) | < 0.001a | |
| N1 | 14 (11.7) | 4 (8.7) | 10 (13.5) | 34 ±18.43 | 34 (0–50) | |||
| N2 | 42 (35) | 2 (4.3) | 40 (54.1) | 64.33 ±20.86 | 60 (24–95) | |||
| N3 | 26 (21.7) | 2 (4.3) | 24 (32.4) | 78.84 ±18.84 | 80 (24–97) | |||
| Stage | ||||||||
| Stage I | 18 (15) | 18 (39.1) | 0 (0) | 0.007b | 6.11 ±5.84 | 10 (0–12) | < 0.001a | |
| Stage II | 28 (23.3) | 20 (43.5) | 8 (10.8) | 20.71 ±16.87 | 21 (0–50) | |||
| Stage III | 42 (35) | 8 (17.4) | 34 (45.6) | 49.95 ±20.15 | 50 (0–80) | |||
| Stage IV | 32 (26.7) | 0 (0) | 32 (43.2) | 87.56 ±6.21 | 89.50 (80–97) | |||
| ITM2A | ||||||||
| Mean ±SD | 40 ±33.94 | 68.26 ±25.16 | 22.43 ±25.96 | < 0.001a | ||||
| Median (range) | 25 (0–90) | 80 (0–90) | 20 (0–90) | |||||
| Low | 64 (53.3) | 0 (0) | 64 (86.5) | < 0.001b | 72.75 ±18.13 | 80 (40–97) | < 0.001a | |
| High | 56 (46.7) | 46 (100) | 10 (13.5) | 16.67 ±15.81 | 16 (0–50) | |||
a
Mann-Whitney U test, b χ2 test